Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Open label

<< Previous

Bullboard Posts

Next >>

Comment by longterm56on Apr 05, 2022 7:06pm

81 Views

Post# 34578589

RE:RE:Open label

SPCEO1 wrote: ... They likely could have told us that months earlier but they curate this info for maximum impact, particularly when a company is in a fundraising mode as TH likely is.

Ha, that's a good one SPCEO ... "they curate this info for maximum impact" ... they seem really effective at that ... lol.

-LT

SPCEO1 wrote: They can tell us anything they want at any time. Common practice in the industry, however, does not lead to a super open discussion of the progress in the trial as we have seen with TH. But they did finally get around to telling us that patient #2 was on the drug for at least 4 cycles (probably more than that) and that is a sizablehint that they have seen agood reaction to TH-1902 with at this one patient. They likely could have toldus that months earlier but they curate this info for maximum impact, particularly when a company is in a fundraising mode as TH likely is.

Biobob wrote: Anyone knows if they can update on Th1902 efficacity signs if they occur in 1a with their open label status. Or is it only in 1b that it's the case.